Neoadjuvant Immunotherapy With Durvalumab in Combination With Tremelimumab in Patients With Muscle-invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms NITIMIB
- 07 Sep 2018 Planned End Date changed from 1 Mar 2027 to 1 Mar 2025.
- 07 Sep 2018 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2020.
- 07 Sep 2018 Status changed from not yet recruiting to recruiting.